New vaccine trial targets deadly diarrhea bug
NCT ID NCT07205926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new vaccine called IVT Shigella-04 to see if it is safe and helps the immune system fight Shigella bacteria, a major cause of severe diarrhea. About 60 healthy adults aged 18 to 49 will receive two shots of either the vaccine or a placebo. Researchers will monitor side effects and measure immune responses over six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medpace Clinical Pharmacology Unit
RECRUITINGCincinnati, Ohio, 45227, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a postbiotic soothe diarrhea in vulnerable kids?
- School health rooms and trained teachers: a new hope for Zambia's children?
- New Stool-Based care pathway aims to tame diarrhea in ICU patients on tube feeding
- Gut bacteria may hold key to chemo side effects
- Weight-Loss drugs may cause hidden anal issues, new study warns
- Gut check: 4,000-Person study links diet, genes, and stomach troubles